基本信息
views: 92
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr Alajez did his post-doctoral work at the Princess Margaret Cancer Center (University Health Network) in Toronto, Canada. His main research interest is to investigate the role of the Polycomb gene family and non-coding microRNAs in driving cancer progression and their potential utilization for targeted therapies. Dr Alajez is a recipient of several prestigious awards and grants and has published more than 53 articles in top-tier ISI-indexed journals including Blood, Cancer Research, Cell Death and Differentiation, Cell Death and Disease, EMBO Molecular Medicine, and in Science Translational Medicine. Dr Alajez currently has more than 2100 citation and an h-index of 24. Prior to his current appointment as Senior Scientist at Qatar Biomedical Research Institute Cancer Center, Dr Alajez was appointed as Associate professor and scientific director at KSU College of Medicine. Dr Alajez main research interest focused on “translational oncology research” with main emphasis on novel biomarker discovery and targeted therapeutics for breast and colorectal cancers.
Research Interests
Dr Alajez main research interests is the discovery of novel tissue and circulating RNA-based biomarkers for breast and colorectal cancer. Additionally, Dr Alajez group is interested in studying the role of microRNA and long noncoding RNAs (lncRNAs) in driving cancer and as potential therapeutic targets. Dr Alajez group is also interested in high-throughput screens (HTS) to identify novel small molecule inhibitors anti-cancer agents, especially those targeting drug-resistant and tumor-initiating cells (or so-called cancer stem cells).
Identification of the microRNA/lncRNA molecular signature associated with pathological complete response to neoadjuvant chemotherapy in Triple Negative (TN) breast cancer (BC).
Circulating microRNAs and lncRNAs as Novel Biomarkers for early breast and colorectal cancer detection.
Cell-based Functional high-throughput small molecule library screens to identify novel therapeutic agents for breast and colorectal cancer.
Research Interests
Dr Alajez main research interests is the discovery of novel tissue and circulating RNA-based biomarkers for breast and colorectal cancer. Additionally, Dr Alajez group is interested in studying the role of microRNA and long noncoding RNAs (lncRNAs) in driving cancer and as potential therapeutic targets. Dr Alajez group is also interested in high-throughput screens (HTS) to identify novel small molecule inhibitors anti-cancer agents, especially those targeting drug-resistant and tumor-initiating cells (or so-called cancer stem cells).
Identification of the microRNA/lncRNA molecular signature associated with pathological complete response to neoadjuvant chemotherapy in Triple Negative (TN) breast cancer (BC).
Circulating microRNAs and lncRNAs as Novel Biomarkers for early breast and colorectal cancer detection.
Cell-based Functional high-throughput small molecule library screens to identify novel therapeutic agents for breast and colorectal cancer.
Research Interests
Papers共 144 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Cancer Researchno. 9_Supplement (2024): PO4-28
BMC Genomicsno. 1 (2024): 1-18
CANCER RESEARCHno. 3 (2024)
FRONTIERS IN ENDOCRINOLOGY (2024): 1360054-1360054
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 4 (2024): 2247
Carlo Bastianutto,Asim Mian,Julie Symes,Joseph Mocanu,Nehad Alajez, Gillian Sleep, Wei Shi,Armand Keating,Michael Crump,Mary Gospodarowicz, Jeff Medin,Mark Minden,
crossref(2023)
International journal of molecular sciencesno. 14 (2023): S499-S499
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn